Belviq, also known as Lorcaserin, is another new weight loss drug approved by the FDA. Lorcaserin helps decrease the intake of food through stimulation of serotonin receptors. The first study (BLOOM or Behavioral Modification and Lorcaserin for Overweight and Obesity Management) showed that that 47.5 percent of patients on Belviq lost five percent or more of their body weight with an average weight loss of 5.8 kg. 20 percent of patients lost five percent or more of their body weight (with an average weight loss of 2.2 kg) in the placebo group.
In July, Qsymia, a combination of phentermine and topiramate), was approved for obese patients or those who are overweight with one weight-related condition such as high blood pressure, diabetes, or cholesterol. Phentermine is a stimulant that suppresses the appetite and topiramate is an anticonvulsant that makes people feel more satisfied after eating.
Qsymia is one of the new anti-obesity drugs approved by the FDA. It is actually a combination of two medications known to help with weight loss: phentermine and topiramate. Phentermine is a stimulant that suppresses the appetite and topirimate is an anticonvulsant that makes people feel more satisfied after eating.
On June 27, a new weight loss drug was approved by the FDA. With the growing problem of obesity in the US, the drug represents a new tool in the treatment of obesity. Called Lorcaserin or Belviq, the drug shows an average weight loss of 5 percent compared to a placebo and is expected to be available before the end of summer, though the FDA does require ongoing study of the medication.
Contrave, a weight-loss medication, was denied approval by the FDA in January of this year. Contrave, a combination of naltrexone and wellbutrin, had been studied in 4500 patients. However, the FDA noted concern about the cardiovascular safety profile of the medication when used long-term in a population of overweight and obese subjects. The FDA is asking for more studies to evaluate the risk/benefit ratio of the drug.